In recent years, we experienced an increasing development of new technologies that aim to comprehensively dissect the molecular genetics of cellular phenotypes. Pioneering studies have been performed on leukemia and lymphoma and then extended to many other types of malignancies. Genome-wide technologies allow taking snapshots of defined cellular context from an unbiased angle highlighting a complexity that we still struggle to fully interpret. The increasing availability of technologies to detect genetic, transcriptional and posttranscriptional characteristics of cellular systems needs to be associated with the development of computational tools to fully investigate these data in an integrated way. The evolution of different genome-wide technologies as well as data mining and integration tools will be discussed following studies performed on normal and malignant human mature B cells. 
Cancer genetics of B-cell lymphomas
As stated by Vogelstein and Kinzler: 'The revolution in cancer research can be summed up in a single sentence: cancer is in essence a genetic disease.' 1 The observation that cancer cells are characterized by genetic aberrations gave birth to the discipline of 'cancer genetics', which aims to dissect the genetic events leading to the malignant transformation. Cancer genetics thus contributed substantially to the discovery of critical genetic lesions in cancer cells, including leukemias and lymphomas. Common recurrent alterations in hematological tumors are represented by reciprocal balanced chromosomal translocations, whose investigation led to the identification of several oncogenes. Chromosomal translocations may cause deregulation of a proto-oncogene by promoter (or regulatory elements) substitution or through generation of gene fusions. The former mechanism is often associated with translocations involving the immunoglobulin (Ig) loci that represent a hallmark in B-cell nonHodgkin lymphomas (B-NHLs). 2 These chromosomal translocations share features suggesting that they may be the results of errors in Ig receptor remodeling processes. These include the V(D)J recombination in immature B cells as well as somatic hypermutation and class switch recombination occurring in mature B cells during the germinal center (GC) reaction. 3 Each stage of B-cell development can be associated with malignant transformation that gives rise to different types of lymphoma and leukemia. However, most mature B-cell malignancies, including Burkitt lymphoma, diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma originate from malignant transformation of GC B cells. 4 Recurrent chromosomal translocations that cause the deregulation of genes controlling GC B-cell development (BCL6) or that lead to the ectopic expression of genes not expressed in normal GC B cells (BCL2, MYC) have been identified in GC-derived B-NHL. Besides chromosomal translocations, other genetic lesions are found in B-NHL, including deletions, amplifications and mutations, many of which still remain uncharacterized. 2 Moreover, in DLBCL, aberrant somatic hypermutation was discovered to introduce mutations into non-Ig loci most likely as a consequence of aberrant activity of the physiological Ig somatic hypermutation mechanism. 5 Although functional consequences of aberrant somatic hypermutation in B-NHL are still the object of investigation, several oncogenes and genes involved in B-cell differentiation have been shown to be targeted by aberrant somatic hypermutation. 6 Overall, the characteristics of the genetic alterations identified in B-NHL suggest that the physiological gene modification processes occurring during the GC reaction have a critical role in the process of malignant transformation. Therefore, the understanding of B-NHL pathogenesis is rooted in the comprehension of normal B-cell physiology.
Oncogenomics
More recently, in the 'omics' era, the framework of cancer genetics has been extended to the study of the whole genome, giving birth to a novel area of investigation named 'oncogenomics'. To fulfill its goal of dissecting the complexity of the oncogenetic events occurring across the whole genome, oncogenomics requires the integration of information from various genome-wide technologies aiming at the analyses of more macromolecules (DNA, RNA, proteins) ( Figure 1 ). The assumption that to be functionally relevant, DNA alterations must affect mRNA and be translated into aberrant proteins has been revisited following the discovery of nonprotein-coding RNA with critical regulatory functions. 7 The identification of an increasing number of genetic and epigenetic mechanisms regulating transcription and translation adds new layers of complexity to the DNA-RNA-protein information flow. Moreover, protein functions can be strongly influenced by posttranslational modifications that add a further layer of complexity to the investigation of protein activities. The first step toward a holistic approach would require the ability to detect all molecules constituting the genome, transcriptome and proteome of each cell type using efficient and sensitive genome-wide approaches. The experimental data then must SPOTLIGHT be integrated toward the reconstruction of cellular networks that provide the framework to gain insights into the functions of single molecules. Obviously, this represents an idealistic prevision; scientists, just beginning to walk this path, are already facing numerous challenges both in the development of adequate technologies for the generation of experimental data as well as in the data analysis. At present, the most realistic solution seems to be the combination of measurable experimental data and computational predictions of cellular models. Only the availability of increasingly exhaustive experimental data will eventually contribute to an improvement in the accuracy of the computational predictions.
The earliest genome-wide technology that has been successfully developed pertains to the analysis of mRNAs (transcriptome). Gene expression profiling (GEP) has been widely used and large amount of data have been made available over the past decade. Multiple bioinformatics tools have been developed and/or adapted for GEP data analysis and, in fact, most attempts for cellular network reconstruction are based on GEP data. More recent is the development of genome-wide strategies to investigate DNA by implementing comparative genomic hybridization with array technology, by using single-nucleotide polymorphisms (SNPs) on a genomic scale or by highthroughput sequencing. Proteome identification is still in its early stage of development and therefore represents a challenge toward whole-genome studies. Overall, at present, GEP data represent the most extensively used genome-wide approach that has been optimized in both experimental design and data analysis.
Molecular characterization of cancer by GEP
The major application of GEP in the cancer field is the molecular classification of malignancies. The feasibility of using GEP for this purpose was first shown in a study that was aimed at distinguishing acute lymphoblastic leukemia from acute myeloid leukemia. This pioneer study showed that it was possible to perform class discovery and class prediction using gene expression data. 8 Indeed, GEP allowed investigators to discriminate acute lymphoblastic leukemia from acute myeloid leukemia and to identify a subset of genes that had predictive power in assigning a sample to the correct class. Class discovery based on GEP was later applied to numerous tumor types, including B-NHL. Several malignancies (for example, B-cell chronic lymphocytic leukemia, hairy cell leukemia and mantle cell lymphoma) have been shown to be characterized by homogenous disease-specific molecular profiles matching the morphological and immunophenotypic classifications. [9] [10] [11] [12] Interestingly, GEP-based class discovery was also able to identify novel molecular subtypes in tumors defined previously as single entity. For instance, GEP recognized distinct molecular types of DLBCL, the most common NHL in adults. 13 A landmark study performed on a lymphoid-specific cDNA array (Lymphochip) identified at least two subgroups of DLBCL: one resembling the GC phenotype (GCB type) and one resembling an activated Bcell phenotype (ABC type). 13 A third group was later defined as primary mediastinal large B-cell lymphoma, 14, 15 whereas a fraction of cases remained unclassified. 16 The molecular classification identifying the GCB and ABC subtypes (Cell Of Origin (COO) classification) showed to be predictive of patient survival with a better prognosis for patients affected by the GCB subtype of DLBCL. An early attempt of validating the COO classification in an independent DLBCL panel using a different GEP platform failed to recognize a correlation between COO and outcome. 17 This inconsistency uncovered the critical role played by the GEP platform and the data analysis approach. Further efforts were required to develop a COO DLBCL subgroups predictor able to classify DLBCL regardless of the GEP platform used. 16 Concordant COO classification of DLBCL has been then performed on different panels of patients further validating the associated prognostic value. Nevertheless, the heterogeneity of DLBCL appears to hide a larger number of molecular entities. Indeed, a study using multiple data analysis methods to recognize robust gene clusters in a panel of 176 GEP identified three DLBCL biological subtypes not related with the cell of origin, but associated with tumor microenvironment and host inflammatory response as defining features of DLBCL. 18 The first cluster (oxidative phosphorylation) was enriched in genes involved in mitochondrial functions, the second cluster was marked by genes involved in the B-cell receptor signaling and proliferation, the third cluster was defined mainly by an associated host response gene signature. The COO classification applied at the same data set was able to discriminate GCB and ABC subtypes and the associated outcome; however, the two classification systems appear to capture different aspects of SPOTLIGHT Figure 1 Schematic representation of information flow from DNA to protein and of regulatory circuits driven by proteins (transcription factors) or not coding RNA (microRNA). The main genome-wide technologies used to investigate macromolecules at each level are reported in boxes.
Investigating cellular networks in mature B cells K Basso DLBCL biology. The patients in the three consensus clusters had similar survival rates, suggesting that these clusters cannot predict response to empiric chemotherapy; they may, however, be useful to identify cluster-specific pathogenetic mechanisms and therapeutic targets. The genetic heterogeneity observed in DLBCL suggests that more molecular subtypes may still remain uncovered and that their dissection is crucial for the development of target therapeutic strategies ( Figure 2) . Overall, the molecular characterization of cancer by GEP aims to identify subsets of genes (gene signatures) whose expression can discriminate across subgroups of patients. The classification power of gene signatures resides in their entirety; nevertheless, single genes included in the signature may be useful as diagnostic or prognostic markers and/or candidate therapeutic targets. For example, several genes whose protein expression is easily detectable by immunohistochemistry have been used to extend the COO classification and the associated prognostic factor to large cohorts of patients regardless of the availability of GEP. 19, 20 Moreover, a few potential candidate therapeutic targets, including PRKCB (protein kinase C, beta) and nuclear factor-kB have been identified by GEP and are at present pursued in targeted therapy for DLBCL. 21 As expected, the identification of gene signatures by GEP highlights the importance of genes that often have unknown function. Only a limited number of protein-coding genes have been deeply investigated and can be functionally associated with cellular phenotypes. The functions of a large majority of transcripts are predicted on the basis of motif similarities. The acquisition of functional data for genes whose expression is associated to molecular subtype of a disease is an essential step in the dissection of the pathogenesis.
Gene expression profiling has added a new level of depth in the analysis of molecular phenotypes by the identification of their gene signatures: the task now is to dissect the functional characteristics associated with a specific gene expression profile.
From descriptive to functional: coexpression networks
Gene expression profiling is a widely used technology and an increasingly large amount of data has been accumulated over the years. Besides using GEP data for molecular classification, class prediction and the identification of candidate prognostic or therapeutic targets, computational biologists attempt to reconstruct biological networks using expression data. GEP data can indeed be used to uncover relationships across genes and gain insights into their regulatory networks. Toward this aim, several methods have been developed within the field of reverse engineering, which seeks to build dynamic models of systems starting from measured static data. Regardless of the inference algorithms that may be used, the main issue remains the type and quantity of data necessary to reconstruct reasonable models. Reverse-engineering methods require large experimental data sets representative of perturbations of the investigated cellular system. GEP generated from human biopsies (normal or malignant tissues) represent a static type of information, giving the expression status of cells in a specific time and condition. To infer the dynamic relationships among genes, it is necessary to overcome the limitations of static information by using GEP data generated not only from experimentally manipulated cells but also from cell types at different stages of differentiation or malignant transformation, which represent naturally occurring in vivo 'manipulations'. A major limitation of GEP-inferred networks is the assumption that mRNA measurements are predictive of molecule activity. This assumption is clearly questionable given the multiple layers of post-transcriptional regulation. Nevertheless, several studies have successfully identified bona fide interactions from GEP data, [22] [23] [24] [25] suggesting that this approach represents a valuable step toward the development of computational models of cellular networks.
Reverse engineering of regulatory networks in mature B cells was performed applying the ARACNe (Algorithm for the Reconstruction of Accurate Cellular Networks) algorithm on a GEP data set, including normal B-cell subpopulations, various Figure 2 Molecular classification of DLBCL by GEP. Biopsies obtained from patients are subjected to morphological/immunophenotypical investigation by expert pathologists who can recognize histological features of DLBCL. GEP performed on the same specimens provides the transcriptional data necessary for the molecular classification. The two present major classification systems (Cell of Origin and Consensus Cluster) are schematically summarized. The molecular heterogeneity of DLBCL still accounts for a number of cases that cannot be assigned to any molecular subtypes.
SPOTLIGHT
Investigating cellular networks in mature B cells K Basso types of B-cell tumors and experimentally manipulated B cells. 22, 26 The inferred network includes approximately 129 000 interactions and suggests a scale-free structure. The scale-free network structure implies that there are few large hubs or master regulators that are highly connected and many minor hubs that influence small sets of genes. The MYC oncogene was identified among the major hubs of the B-cell network and the analysis of MYC connectivity allowed the identification of previously reported as well as novel MYC target genes. The ability to infer a MYC subnetwork in the larger context of the B-cell network implies that the GEP data set is informative on MYC dynamic connectivity. Indeed, the data set including normal GC B cells (lacking MYC expression) and various malignant B cells (with variable level of MYC expression) provided the necessary perturbations that are required to infer dynamic relationships from static GEP data. As ARACNe identifies statistical dependencies between genes, the inferred relationships are not restricted to transcriptional targets. Indeed, a fraction of large hubs, including PRKCB, was represented by molecules that are not transcription factors. The critical role of PRKCB in B cells was shown in PRKCB-deficient mice that have impaired humoral and B-cell proliferative responses. 27, 28 Moreover, PRKCB overexpression was observed in fatal/refractory DLBCL, suggesting its involvement in the pathogenesis of lymphomas. 17 The present interest for PRKCB as candidate therapeutic target should consider the large impact that alterations of this gene expression may cause and eventually try to model, in a network context, the consequences to optimize a therapeutic approach.
In transcriptional networks computed from GEP data, the discrimination between direct and indirect transcriptional regulations is inferred and depends on the strength of the statistical dependence across transcripts. The study of specific transcription factor subnetworks discriminating between direct and indirect target genes has been made possible by integrating data from chromatin immunoprecipitation (ChIP) assays, which allow to identify DNA-binding sites for a given transcription factor. The genome-wide flavor of this technique (ChIP-on-chip) is based on the detection of the bound genomic regions using arrays containing probes for gene promoters. Combination of ChIP-on-chip and GEP analysis has shown effective in dissecting the role of specific transcription factors in regulating cellular pathways. 25, 29 However, to be useful in the implementation of genome-wide GEP-based inferred networks, ChIP-on-chip data should be generated for all possible transcription factors in multiple phenotypes. At present, this is still technically unfeasible due to the dependency of the method on appropriate antibodies for each individual transcription factor.
Computationally reconstructed cellular networks may be used as framework to identify interactions that are aberrant in a specific phenotype versus the overall network (Figure 3) . Such deregulations may point to genes playing critical roles in oncogenesis as well as to targets and effectors of specific biochemical perturbations. A computational tool developed to address this issue is represented by the IDEA (Interactome Dysregulation Enrichment Analysis) algorithm. 30 IDEA identifies, for each interaction in a network, changes associated to each phenotype of interest. A given correlation may become stronger (gain of correlation) or weaker (loss of correlation) when a given phenotype is added to the data set. Each gene is then ranked according to the number of dysregulated correlations identified in a specific phenotype. IDEA, applied to different types of B-NHL (Burkitt lymphoma, follicular lymphoma, MCL) in a B-cell network context, was able to identify within the top ranked deregulated genes the oncogenes (MYC, BCL2, CCND1) that are classically associated to the pathogenesis of these diseases. 30 This approach proves to be effective in retrieving aberrant molecular interactions that does not necessarily reflect into differential expression. IDEA attempts the analysis of portions of a cellular network that behave differently in a given phenotype and might therefore point to critical altered nodes even providing initial clues to guide further functional investigation on previously uncharacterized genes.
Multiple levels of information, including genetic, transcriptional, epigenetic and functional data, are suitable to be incorporated into network structures and this may be a necessary step to uncover complex behaviors associated with multifactorial diseases. Probabilistic frameworks combining genetic linkage data with literature-based molecular interaction networks have been used to investigate complex diseases, such as Alzheimer, autism, bipolar disorder and schizophrenia, 31, 32 and similar approaches may be applied to cancer.
Overall, the present human inferred transcriptional networks are largely constrained by limited experimental data; nevertheless, they have been shown to represent an initial step in the dissection of the biological complexity of cellular systems.
Studying the genome by high-throughput and high resolution assays
The complete genetic information of an organism is stored in its DNA. Coordinated scientific and economical efforts have led to the complete sequencing of the human genome. However, it seems that we will need more than a handful of complete human genome sequences to truly dissect the complexity of our genome.
Alterations at the DNA level can modify the coding properties of a cell and are at the basis of malignant transformation. Multiple methods have been developed to study alterations at the level of DNA in increasingly sophisticated ways. The classic G-banding staining on metaphases has been supplanted by spectral karyotyping (SKY) that allows the detection and characterization of complex rearrangements. Higher resolution has been obtained by the introduction of comparative genomic hybridization, which aims to identify gains and losses of genetic material between normal tissues and tumor specimens from the same patient. The original method based on metaphase hybridization has been improved and made more sensitive by the use of high-density array-comparative genomic hybridization. This approach has been used to investigate a number of different malignancies, including lymphomas. Studies on DLBCL have shown that molecular subtypes, as defined by GEP, are associated with distinct patterns of genomic alterations. In particular, specific genetic aberrations have been identified in the ABC and GCB types of DLBCL and subsequently coupled with expression data. Thirty out of 272 recurrent genetic aberrations associated with gene-expression alterations were differentially identified in these DLBCL subtypes. 33 Moreover, several chromosomal aberrations were associated with clinical outcome. Interestingly, gene-expression signatures that reflect features of the malignant cells (for example, proliferation signature) or nonmalignant infiltrating cells (for example, T-cell signature) have been associated with specific chromosomal alterations. 34 However, no key regulatory genes have been detected in the affected genomic regions that could explain the changes in the associated gene signatures. This may be due to the fact that the function of many protein-coding genes is elusive as well as to the possibility that nonprotein-coding genes
SPOTLIGHT
Investigating cellular networks in mature B cells K Basso (for example, microRNA) may be affected by these genetic lesions. Indeed, genetic aberrations involving microRNA loci could affect post-transcriptionally many genes that may include critical transcription factors regulating 'signature genes' associated with specific functions.
In an attempt to further increase the resolution of the detection of genetic aberrations and to acquire the ability to detect both copy number variation and loss of heterozygosity in a single assay, new methods based on the detection of SNPs have been developed. The human genome project has made available hundreds of thousands of potentially informative SNP sites that can be used as markers in whole genome analysis. Early studies using high-resolution SNP arrays have been performed on acute lymphoblastic leukemia and chronic lymphocytic leukemia. 35, 36 These studies confirmed the role of several genetic alterations and identified new molecular lesions in these cancer types. The integration of GEP and highresolution SNP array data are at present widely applied, and the results appear to be promising for the identification of genetic lesions that may have a driving role in the pathogenesis of cancer.
The recent development of massive parallel sequencing methods has increased the speed of sequencing dramatically. This new technology is still evolving to further improve the speed, accuracy and length of sequenced fragments and, at the same time, to decrease the costs. At present, it is possible to sequence a complete human genome in approximately 4 weeks for $100 000. To undertake large-scale whole-genome sequencing analyses, the technology requires further improvements and it must become even more affordable. In the meantime, deep sequencing can be used to investigate portions of the genome. A particularly appealing approach available at present is to perform mutational analysis on a large scale for a few hundreds of genes by gene-capture systems. Briefly, the genomic regions of interest are first trapped on custom arrays and then subjected to sequencing. This rapid resequencing allows investigation of selected parts of the human genome in multiple patients and at present represents an affordable intermediate step toward the mass market of whole genome sequencing. These high-throughput sequencing technologies are suitable not only for whole genome sequencing, but also for whole transcriptome sequencing and whole genome ChIP assays. In the relatively near future, we may experience a new revolution in genome-wide technologies moving from arrays to high-throughput sequencing.
Integration of data from multiple sources
In order to fully explore the potentials of systems biology, it is essential to integrate large experimental data set toward the computational reconstruction of dynamic cellular networks. This ambitious plan depends on the existence of well-annotated data sets that include detailed information on the single cellular components (that is, gene, transcripts and proteins). Unfortunately, at present, systems biology can rely on sparse experimental data and suboptimal annotations.
The first issue is represented by the quality of the available data. Present high-throughput technologies can produce information from different cellular levels: DNA, RNA and SPOTLIGHT Figure 3 Computational reconstruction of cellular networks. At present, the large availability of gene expression data allows the reconstruction of transcriptional networks that capture interactions among genes on the basis of their transcriptional expression pattern. In the near future, the availability of data from multiple cellular levels will require the ability to integrate the data toward the reconstruction of more complex cellular networks. These networks can represent the framework to identify interactions that are aberrant in a specific phenotype versus the overall network.
Investigating cellular networks in mature B cells K Basso proteins. Unfortunately, the technologies that should enable a genome-wide detection of different macromolecules are at different stages of development. For example, the availability of good-quality transcriptional data contrasts with the limited amount of data from the protein level. Therefore, data integration at present lacks essential experimental information to connect the transcriptome to the proteome. Moreover, the multiple layers of regulation occurring in a cell system have not yet been fully addressed experimentally.
A second issue is represented by the annotations. Structured bioinformatics databases are essential for the proper interpretation of high-throughput data; nevertheless, their coherence is still suboptimal and the use of common, controlled vocabularies as well as the development of standards for annotations is a need for the development of the field.
The generation of genome-wide data is only destined to increase especially with the recently developed new technologies. The large amount of experimental data will need efficient storage, mining and integration tools to allow the functional understanding of cellular systems.
Future directions and perspectives
An effective approach to cope with biological complexity is to consider biology as an informational science that requires acquisition, mining and integration of biological data. It is on this view that the development of systems biology is founded. The final goal of systems biology is to develop computational models of cellular networks that may be useful in predicting network alterations that are at the basis of pathogenesis and that may eventually guide the development of appropriate therapeutic intervention. It is hoped that systems biology will lay the foundations for systems medicine, which is considered a new way of integrating biological data through computational and mathematical tools toward the development of a personalized and predictive medicine. The process is still in an early stage, and systems biology is constrained by limited data and suboptimal mining and integration tools. We are rapidly acquiring new technologies to increase the amount of biological data, and the availability of data will further boost the development of computational tools to mine and integrate them. The investigation of novel data will provide the basis for a deeper knowledge of our genome, transcriptome, proteome and of the numerous regulatory mechanisms acting at different levels. Addressing biological complexity requires extensive efforts in integrating not only data but also expertise from different fields in a truly collaborative environment.
